PT-141 (Bremelanotide) (10 mg Vial) Dosage Protocol
PT-141 is a melanocortin receptor agonist (MC3R/MC4R) studied for sexual arousal and erectile function. Acts via the central nervous system rather than vascular mechanisms.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Educational guide for reconstitution and daily dosing
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–8 | 500 mcg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 9–12 | 1000 mcg (1.0 mg) | 30 units (0.30 mL) |
| Weeks 13–16 | 1500 mcg (1.5 mg) | 45 units (0.45 mL) |
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week daily protocol with gradual titration.
| Item | Quantity |
|---|---|
| Peptide Vials (PT-141, 10 mg each) | 8 weeks (56 days × 500 mcg = 28 mg) ≈ 3 vials 12 weeks (56 × 500 + 28 × 1000 = 56 mg) ≈ 6 vials 16 weeks (56 × 500 + 28 × 1000 + 28 × 1500 = 98 mg) ≈ 10 vials |
| Insulin Syringes (U-100) | Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes |
| Bacteriostatic Water (10 mL bottles) | 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles 16 weeks (10 vials): 30 mL → 3 × 10 mL bottles |
| Alcohol Swabs | Per week: 14 swabs (2/day) 8 weeks: 112 swabs → recommend 2 × 100-count boxes 12 weeks: 168 swabs → recommend 2 × 100-count boxes 16 weeks: 224 swabs → recommend 3 × 100-count boxes |
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 28 days, protect from light |
Important Notes
How This Works
PT-141 is a cyclic heptapeptide analog of α-MSH. It activates melanocortin-3 (MC3R) and melanocortin-4 (MC4R) receptors in the hypothalamus and limbic system, producing sexual motivation and arousal centrally.
The mechanism distinguishes PT-141 from PDE5 inhibitors (sildenafil/tadalafil) which work peripherally on vascular smooth muscle. PT-141 can produce desire and arousal even without physical stimulation.
Potential Benefits & Side Effects
Potential Benefits
- Studied for hypoactive sexual desire disorder (HSDD) in premenopausal women.
- Phase 2/3 trials in males with erectile dysfunction.
- CNS mechanism distinct from vascular PDE5 inhibition.
- Effects last 6–12 hours from a single dose.
Side Effect Profile
- Nausea (most common — ~40% in trials).
- Flushing, headache.
- Transient hypotension.
- Pre-treatment with ondansetron 4 mg oral 30 min prior reduces nausea.
Lifestyle Factors
- Inject 30–45 minutes before desired effect.
- Maximum once per 24 hours.
- Pre-treatment with antiemetic for first few uses if nausea-prone.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm.
- 90° angle with short insulin needle.
- Bring to room temperature before injecting.